GREENWICH LIFESCIENCES, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
GREENWICH LIFESCIENCES, INC. (GLSI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.48M, a 3.85% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.54M, a 0.00% change year-over-year.
- GREENWICH LIFESCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.54M.
- GREENWICH LIFESCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $1.54M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month |
|---|---|---|
| 2026-06-30 | $1.48M 10-Q · filed 2026-08-11 | $3.03M derived: sum of 2 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.54M 10-Q · filed 2026-08-11 | |
| 2025-06-30 | $1.54M 10-Q · filed 2026-08-11 | $3.09M derived: sum of 2 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.54M 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |